elongation factor for RNA polymerase II 2 pseudogene 1Genealiases: []
Q-omics provides the consensus-scored ELL2P1 profile across patient tissues and cancer cell-line models. ELL2P1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ELL2P1 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, ELL2P1 RNA expression shows 17,517 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, and THYM as cancer lineages where ELL2P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ELL2P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ELL2P1 survival associations across molecular data types. ELL2P1 RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ELL2P1 RNA expression–survival associations across cancer types. High ELL2P1 expression shows unfavorable associations in KICH, ACC and KIRP, but favorable associations in KIRC, SKCM and PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ELL2P1 RNA expression.
This table summarizes ELL2P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ELL2P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ELL2P1 shows lower tumor expression in COAD, THCA, ESCA and READ and higher tumor expression in KIRC and LUAD. The KIRC box plot shows higher ELL2P1 RNA expression in tumor versus normal tissue (log2 FC = +0.362, t-test p < 0.001).
This table shows molecular features associated with ELL2P1 in patient tissues and cancer cell lines. In patient samples, ELL2P1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
